Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Ulta Beauty Inc (ULTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Ulta Beauty Inc — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while Ulta Beauty Inc trades at $593 (market cap $24.76B). The key difference: Ulta Beauty Inc is far larger — about 3.3× Spyre Therapeutics Inc. Common Stock's market cap, and Ulta Beauty Inc is more actively traded (507,422 versus 1,441,031). Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Ulta Beauty Inc for 92 Days on average.
| SYRE | ULTA | |
|---|---|---|
Market Cap | $7.52B | $24.76B |
Volume | 1,441,031 | 507,422 |
Sector | Health | Consumer Cyclical |
52-Week High | $108.92 | $706.82 |
52-Week Low | $22.18 | $450.75 |
Typical Hold Time | 0 Days | 92 Days |
Enterprise Value | $6.52B | $27.07B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
ULTA stock trades at $592.42, up 4.4% on the day, reflecting strong momentum after recent earnings beats and raised guidance. The technical outlook is bullish, with the current price near resistance at $589. Fundamentally, the company shows robust profitability with a 9.34% net margin and 46.12% ROE, though revenue growth has moderated. Analyst sentiment remains positive with a consensus price target of $624.93 and 60% buy ratings, supported by e-commerce strength and expansion into wellness categories.
The outlook for ULTA is favorable, driven by e-commerce acceleration and strategic initiatives, but risks include margin pressure from promotions and flat store traffic. Valuation at a P/E of 21.09 appears reasonable given growth prospects, yet execution on new categories and macroeconomic sensitivity to consumer spending are key watchpoints for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Ulta Beauty Inc
With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →
